 This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria is designed to provide data on an AH7N9 vaccine made with HA antigen derived from the influenza AShanghai22013 virus. The study aims to address several critical questions, including the safety, reactogenicity, and immunogenicity of a monovalent influenza AH7N9 virus vaccine manufactured by Sanofi Pasteur: 1 two doses administered at different dosages 3.75, 7.5, or 15 mcg of HA0.5 mL dose given with AS03 adjuvant manufactured by GlaxoSmithKline Biologicals or without adjuvant 15 mcg of HA0.5 mL dose and 45 mcg of HA0.75 mL dose; and 2 a combination of two doses of the AH7N9 vaccine 15 mcg of HA0.5 mL dose each administered with a different adjuvant AS03 or MF59 manufactured by Novartis Vaccines and Diagnostics; and 3 two doses administered at 15 mcg of HA0.5 mL dose given with MF59 adjuvant manufactured by Novartis Vaccines and Diagnostics. 